{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:28:41Z","timestamp":1786638521387,"version":"build-2736575974"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Blood-based biomarkers (BBM) provide minimally invasive, scalable, lower-cost tools for identifying neurodegenerative diseases, but prospective data on their clinical validity in memory clinic settings are limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate how a tailored plasma BBM panel (phosphorylated tau 181 [pTau181], glial fibrillary acidic protein [GFAP], and neurofilament light chain [NfL]) during multidisciplinary diagnostic meetings is associated with syndrome diagnosis, suspected etiology, and clinician confidence.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective diagnostic study enrolled consecutive patients whose BBM were presented during weekly multidisciplinary meetings after standard workup (clinical assessment, neuropsychological testing, and brain magnetic resonance imaging) from September 2023 to October 2024 at 3 academic memory clinics in the Netherlands. When available, cerebrospinal fluid (CSF) and amyloid positron emission tomography (PET) results were subsequently shown. Findings were categorized as high, intermediate, or low probability for Alzheimer disease (AD), frontotemporal lobar degeneration (FTD), or dementia with Lewy bodies (DLB). Data were analyzed from December 2024 to July 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n BBM (pTau181, GFAP, and NfL) measured weekly and analyzed jointly as a diagnostic panel.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Outcomes of interest were changes in suspected syndrome diagnoses, primary etiology, and clinician confidence before vs after BBM disclosure.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 450 patients (mean [SD] age, 66 [10] years; 183 [41%] female; mean [SD] MMSE score, 25 [5]) were enrolled. Among 356 patients (79%) with AD as the primary suspected etiology, assessment of BBM classified 149 patients (42%) as high, 101 patients (28%) as intermediate, and 106 patients (30%) as low probability of AD. Median (IQR) diagnostic confidence in the total cohort increased from 80% (70%-90%) to 90% (70%-90%) after BBM disclosure (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), increasing in 207 patients (46%), unchanged in 175 patients (39%), and decreasing in 68 patients (15%). Following BBM disclosure, syndrome diagnoses were revised in 6 patients (1%) and primary etiology was revealed in 23 patients (5%): 11 diagnoses (2%) shifted to AD, 3 diagnoses (1%) from AD to no neurodegeneration, 2 diagnoses (&amp;lt;1%) from AD to FTD, and 7 diagnoses (2%) became unclear. Among 450 patients, 234 (52%) had CSF and amyloid PET results. Using this as reference, BBM analyzed with an amyloid-positive vs amyloid-negative tool identified 76% amyloid positives and 85% amyloid negatives for high- and low-probability results, respectively; intermediate results occurred in 24% and 39%, respectively.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this prospective diagnostic study, a BBM panel was associated with altered etiologic diagnoses in a few patients and was associated with increased diagnostic confidence overall. These findings suggest that BBM may help refine the diagnostic process within specialized academic memory clinics.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.28864","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:30:28Z","timestamp":1786635028000},"page":"e2628864","source":"Crossref","is-referenced-by-count":0,"title":["Plasma Alzheimer Biomarkers and Diagnostic Decision-Making in Memory Clinics"],"prefix":"10.1001","volume":"9","author":[{"given":"Sinthujah","family":"Vigneswaran","sequence":"first","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"},{"name":"Alzheimer Center Amsterdam, Neurology department, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M. W.","family":"Verberk","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Boonkamp","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne","family":"in \u2018t Veld","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen J. A.","family":"Koel-Simmelink","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Antwi-Berko","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"van Unen","sequence":"additional","affiliation":[{"name":"Department of Neurology and Alzheimer Center Erasmus MC University Medical Center Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Rousset","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Claessen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"},{"name":"Alzheimer Center Amsterdam, Neurology department, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa D.","family":"Zwan","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology department, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology department, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Clinical Memory Research Unit, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wilson","sequence":"additional","affiliation":[{"name":"Quanterix Corporation, Billerica, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afina W.","family":"Lemstra","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology department, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande A. L.","family":"Pijnenburg","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology department, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"},{"name":"Alzheimer Nederland, Amersfoort, the Netherlands"},{"name":"Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Public Health, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majon","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC Location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mattace-Raso","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Erasmus MC University Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne M.","family":"Papma","sequence":"additional","affiliation":[{"name":"Department of Neurology and Alzheimer Center Erasmus MC University Medical Center Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harro","family":"Seelaar","sequence":"additional","affiliation":[{"name":"Department of Neurology and Alzheimer Center Erasmus MC University Medical Center Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argonde C.","family":"van Harten","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam, Neurology department, Vrije Universiteit Amsterdam, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"4","key":"zoi260786r1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"10284","key":"zoi260786r2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease.","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"zoi260786r3","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup.","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"10004","key":"zoi260786r4","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","article-title":"Lewy body dementias.","volume":"386","author":"Walker","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"zoi260786r5","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/alz.12643","article-title":"New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia.","volume":"18","author":"Del Campo","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"2","key":"zoi260786r6","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12464","article-title":"Clinical value of Alzheimer\u2019s disease biomarker testing.","volume":"10","author":"Patel","year":"2024","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"zoi260786r7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation.","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"9","key":"zoi260786r8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis.","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol"},{"issue":"11","key":"zoi260786r9","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/acn3.51676","article-title":"Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface.","volume":"9","author":"Vermunt","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"zoi260786r10","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u00df but not tau pathology in Alzheimer\u2019s disease.","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"1","key":"zoi260786r11","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light.","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"zoi260786r12","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u00df pathology in preclinical Alzheimer\u2019s disease.","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"zoi260786r13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology.","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"5","key":"zoi260786r14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"issue":"17","key":"zoi260786r15","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u00df-amyloid 42\/40 predicts current and future brain amyloidosis.","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"9","key":"zoi260786r16","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1002\/alz.14088","article-title":"Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice.","volume":"20","author":"Verberk","year":"2024","journal-title":"Alzheimers Dement"},{"key":"zoi260786r17","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.885787","article-title":"Sex-specific associations of diabetes with brain structure and function in a geriatric population.","volume":"14","author":"Thomas","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"zoi260786r18","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1177\/10731911251339362","article-title":"Cognitive performance in Parkinson\u2019s spectrum disorders: a comparative study of patients with Parkinson\u2019s disease, Parkinson\u2019s disease dementia, dementia with Lewy bodies, progressive supranuclear palsy, and corticobasal syndrome.","volume":"33","author":"van Breugel","year":"2026","journal-title":"Assessment"},{"issue":"3","key":"zoi260786r19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","article-title":"Amsterdam Dementia Cohort: performing research to optimize care.","volume":"62","author":"van der Flier","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"zoi260786r20","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","article-title":"A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease.","volume":"10","author":"Jessen","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi260786r21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"11","key":"zoi260786r22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants.","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"zoi260786r23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"2","key":"zoi260786r24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000112852","article-title":"Diagnostic accuracy of consensus diagnostic criteria for frontotemporal dementia in a memory clinic population.","volume":"25","author":"Pijnenburg","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"zoi260786r25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","article-title":"Diagnostic criteria for vascular cognitive disorders: a VASCOG statement.","volume":"28","author":"Sachdev","year":"2014","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"zoi260786r26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration.","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"issue":"6","key":"zoi260786r27","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov Disord"},{"issue":"22","key":"zoi260786r28","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","article-title":"A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking.","volume":"73","author":"Teunissen","year":"2009","journal-title":"Neurology"},{"key":"zoi260786r29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.dadm.2017.04.007","article-title":"Consensus guidelines for lumbar puncture in patients with neurological diseases.","volume":"8","author":"Engelborghs","year":"2017","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"zoi260786r30","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12182","article-title":"Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status.","volume":"13","author":"Willemse","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"issue":"8","key":"zoi260786r31","doi-asserted-by":"publisher","first-page":"e860","DOI":"10.1212\/WNL.0000000000201597","article-title":"Diagnostic performance and clinical applicability of blood-based biomarkers in a prospective memory clinic cohort.","volume":"100","author":"Sarto","year":"2023","journal-title":"Neurology"},{"issue":"6","key":"zoi260786r32","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/alz.13022","article-title":"Prospective evaluation of plasma phosphorylated tau in a real-life memory clinic in Thailand.","volume":"19","author":"Thanapornsangsuth","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"15","key":"zoi260786r33","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect alzheimer disease in primary care and secondary care.","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"zoi260786r34","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70289","article-title":"Disclosure of plasma p-tau217 measure improves diagnostic confidence in patients with Alzheimer\u2019s disease versus syndromes associated with frontotemporal lobar degeneration.","volume":"21","author":"Cantoni","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"11","key":"zoi260786r35","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70891","article-title":"Blood-based Alzheimer\u2019s disease biomarkers in a behavioral neurology clinic: real-world implementation, clinical utility, and diagnostic performance.","volume":"21","author":"Prufer Q C Araujo","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi260786r36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-024-01474-z","article-title":"Plasma biomarkers increase diagnostic confidence in patients with Alzheimer\u2019s disease or frontotemporal lobar degeneration.","volume":"16","author":"Altomare","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"zoi260786r37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology\u2014recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease.","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"zoi260786r38","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70003","article-title":"Performance of plasma p-tau217 and NfL in an unselected memory clinic setting.","volume":"16","author":"Rousset","year":"2024","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"zoi260786r39","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.13399","article-title":"Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.","volume":"136","author":"Ishiki","year":"2016","journal-title":"J Neurochem"},{"issue":"2","key":"zoi260786r40","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14458","article-title":"Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer\u2019s disease pathology among cognitively impaired and unimpaired: a systematic review and meta-analysis.","volume":"21","author":"Khalafi","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"3","key":"zoi260786r41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jalz.2016.09.012","article-title":"Implementation of subjective cognitive decline criteria in research studies.","volume":"13","author":"Molinuevo","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"11","key":"zoi260786r42","doi-asserted-by":"publisher","first-page":"8209","DOI":"10.1002\/alz.14150","article-title":"Considerations for widespread implementation of blood-based biomarkers of Alzheimer\u2019s disease.","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"9","key":"zoi260786r43","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u00df positivity with further confirmatory testing only in uncertain cases.","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2852732\/vigneswaran_2026_oi_260786_1785962759.14146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:30:29Z","timestamp":1786635029000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2852732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.28864","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}